Prestige Consumer Healthcare Inc. (NYSE:PBH) Receives $80.60 Average Price Target from Analysts

Prestige Consumer Healthcare Inc. (NYSE:PBH) has earned a consensus recommendation of “Hold” from the seven analysts that are presently covering the stock, MarketBeat Ratings reports. Four investment analysts have rated the stock with a hold rating and three have issued a buy rating on the company. The average 12-month target price among brokers that have covered the stock in the last year is $80.60.

Several analysts have commented on PBH shares. Canaccord Genuity Group dropped their target price on shares of Prestige Consumer Healthcare from $100.00 to $88.00 and set a “buy” rating on the stock in a report on Friday, November 7th. Jefferies Financial Group dropped their price objective on shares of Prestige Consumer Healthcare from $70.00 to $66.00 and set a “hold” rating on the stock in a report on Friday, January 30th. Oppenheimer dropped their price target on Prestige Consumer Healthcare from $82.00 to $72.00 and set an “outperform” rating on the stock in a research note on Tuesday, October 21st. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Prestige Consumer Healthcare in a research report on Thursday, January 22nd. Finally, Zacks Research upgraded Prestige Consumer Healthcare from a “strong sell” rating to a “hold” rating in a research note on Monday, November 10th.

Insider Activity

In other news, VP Jeffrey Zerillo sold 719 shares of the business’s stock in a transaction on Friday, November 28th. The shares were sold at an average price of $60.00, for a total value of $43,140.00. Following the sale, the vice president owned 42,329 shares of the company’s stock, valued at $2,539,740. The trade was a 1.67% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 1.40% of the stock is owned by company insiders.

Institutional Investors Weigh In On Prestige Consumer Healthcare

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. King Luther Capital Management Corp boosted its stake in shares of Prestige Consumer Healthcare by 150.3% during the 4th quarter. King Luther Capital Management Corp now owns 90,968 shares of the company’s stock worth $5,612,000 after buying an additional 54,621 shares during the last quarter. Royce & Associates LP raised its holdings in Prestige Consumer Healthcare by 68.3% during the fourth quarter. Royce & Associates LP now owns 97,750 shares of the company’s stock worth $6,030,000 after acquiring an additional 39,685 shares in the last quarter. Bleakley Financial Group LLC boosted its position in Prestige Consumer Healthcare by 15.6% during the fourth quarter. Bleakley Financial Group LLC now owns 12,617 shares of the company’s stock valued at $778,000 after purchasing an additional 1,705 shares during the last quarter. New Age Alpha Advisors LLC acquired a new position in Prestige Consumer Healthcare during the fourth quarter valued at approximately $422,000. Finally, Hantz Financial Services Inc. grew its stake in Prestige Consumer Healthcare by 71.6% in the fourth quarter. Hantz Financial Services Inc. now owns 1,170 shares of the company’s stock valued at $72,000 after purchasing an additional 488 shares in the last quarter. 99.95% of the stock is currently owned by institutional investors and hedge funds.

Prestige Consumer Healthcare Stock Performance

Shares of Prestige Consumer Healthcare stock opened at $65.49 on Friday. The stock’s fifty day simple moving average is $63.30 and its 200 day simple moving average is $63.81. The company has a current ratio of 3.11, a quick ratio of 1.93 and a debt-to-equity ratio of 0.58. The company has a market capitalization of $3.10 billion, a PE ratio of 17.33, a PEG ratio of 2.09 and a beta of 0.43. Prestige Consumer Healthcare has a 12 month low of $57.25 and a 12 month high of $90.04.

Prestige Consumer Healthcare (NYSE:PBH) last posted its earnings results on Thursday, February 5th. The company reported $1.14 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.16 by ($0.02). The business had revenue of $283.44 million during the quarter, compared to analyst estimates of $286.93 million. Prestige Consumer Healthcare had a net margin of 16.90% and a return on equity of 12.02%. The firm’s revenue was down 2.4% on a year-over-year basis. During the same period in the previous year, the firm posted $1.22 earnings per share. Prestige Consumer Healthcare has set its FY 2026 guidance at 4.540-4.540 EPS. On average, research analysts predict that Prestige Consumer Healthcare will post 4.5 EPS for the current year.

About Prestige Consumer Healthcare

Prestige Consumer Healthcare, Inc is a leading manufacturer and marketer of branded over-the-counter (OTC) healthcare products. The company focuses on developing, acquiring and commercializing a diverse portfolio of non-prescription remedies designed to address common consumer health needs, including pain relief, cold and cough, digestive health, eye care, skin care and women’s health.

Key brands in Prestige’s portfolio include Clear Eyes (eye health), Carmex (lip care), Chloraseptic (sore throat relief), Dramamine (motion sickness), Rolaids (antacid), Monistat (women’s health), BC Powder (pain relief), Little Remedies (pediatric cold and gas relief) and TheraTears (dry eye therapy).